A previous study reported that use of GLP-1 receptor agonists was associated with lower all-cause mortality, cardiovascular-related mortality, and kidney failure compared with placebo in the general population with diabetes.7 In that study, use of GLP-1 receptor agonists was also associated with improved outcomes compared with several traditional antidiabetic agents, including sulfonylureas, DPP-4 inhibitors, and thiazolidinedione. The gene discussed is GLP1R; the disease is kidney failure.